AliveCor has announced that the US Centers for Medicare & Medicaid Services (CMS) has included the company’s artificial intelligence (AI)-powered electrocardiogram (ECG) technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule, assigning it to Ambulatory Payment Classification (APC) 5733.
This approval enables hospital outpatient settings to receive a Medicare payment rate of US$59.40 when the US Food and Drug Administration (FDA)-cleared Kardia 12L ECG system is used to perform 12-lead ECGs, as noted in a recent AliveCor press release.
“Cardiovascular disease remains the leading cause of death in the USA, and CMS’ decision to set a Medicare payment rate for the AI-powered ECG represents a major step toward broadening access to this potentially life-saving heart health technology,” said Sanjay Voleti, chief business officer at AliveCor. “By leveraging advanced AI to diagnose more conditions than ever, the reliable and easy-to-use Kardia 12L ECG system sets a new standard in cardiac care, democratising access to critical heart data and highlighting the value of widespread ECG use in clinical practice.”
This approval is in addition to the Category III Current Procedural Terminology (CPT) codes that were granted by the American Medical Association (AMA) for government payers, including Medicare and Medicaid, and commercial insurance companies to identify healthcare services and procedures for reimbursement.
